8-K: SI-BONE Reports Record Q4 Financial Results and Issues Optimistic 2025 Guidance

SI-BONE announces strong Q4 2024 results with 26% worldwide revenue growth and positive adjusted EBITDA, alongside promising 2025 financial guidance.

Summary

• SI-BONE, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Worldwide revenue for Q4 2024 reached $49.0 million, a 26% increase year-over-year.
• U.S. revenue for Q4 2024 was $46.9 million, reflecting a 28% increase year-over-year.
• The company achieved a gross margin of approximately 79% in Q4 2024.
• SI-BONE reported a net loss of $4.5 million for Q4 2024, an improvement of 59% compared to the previous year.
• Adjusted EBITDA for Q4 2024 was positive at $1.9 million, a 139% improvement year-over-year.
• For the full year 2024, worldwide revenue was $167.2 million, a 20% increase from 2023.
• U.S. revenue for the full year 2024 was $158.4 million, a 21% increase from 2023.
• The net loss for the full year 2024 was $30.9 million, a 29% improvement compared to 2023.
• Adjusted EBITDA loss for the full year 2024 was $5.1 million, a 71% improvement compared to 2023.
• SI-BONE ended the year with $150.0 million in cash and equivalents.
• The company expects 2025 worldwide revenue to be in the range of $193.5 million to $195.5 million, representing a growth of 16% to 17%.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability, and optimistic guidance for the future. The company's strategic initiatives and market position contribute to a favorable sentiment.

Positives

• Significant revenue growth was achieved in both Q4 and full year 2024.
• The company demonstrated substantial improvement in adjusted EBITDA, turning positive in Q4.
• Gross margins remained consistently high at approximately 79%.
• SI-BONE has a strong cash position with $150.0 million in cash and equivalents.
• The company is projecting continued revenue growth and positive adjusted EBITDA for 2025.
• SI-BONE is expanding its reach with an increasing number of active physicians using their products.
• The company is receiving favorable reimbursement status and breakthrough device designations.

Negatives

• SI-BONE reported a net loss of $4.5 million for Q4 2024, although it represents a significant improvement year-over-year.
• The company reported an adjusted EBITDA loss of $5.1 million for the full year 2024, although it represents a significant improvement year-over-year.
• International revenue for Q4 2024 was $2.1 million compared to $2.2 million in the corresponding period in 2023.

Risks

• The company's ability to introduce and commercialize new products and indications could impact future performance.
• Maintaining favorable reimbursement for procedures using SI-BONE's products is crucial for continued growth.
• Economic weakness could affect patients' ability and desire to undergo elective procedures.
• Risks to the supply chain could impact the company's ability to meet demand.
• Future capital requirements for new surgical systems could strain resources.
• The pace of re-normalization of the healthcare operating environment could impact procedure volumes.

Future Outlook

SI-BONE expects 2025 worldwide revenue to be in the range of $193.5 million to $195.5 million, implying year-over-year growth of approximately 16% to 17%. The company anticipates delivering positive adjusted EBITDA for the second half and full year 2025.

Management Comments

• Laura Francis, Chief Executive Officer, stated that 2024 was a transformative year for SI-BONE, with years of innovation, strategic investments, and disciplined execution delivering meaningful results.
• Laura Francis mentioned that over 2,000 U.S. physicians performed a SI-BONE procedure last year, improving the lives of nearly 18,000 patients.
• Laura Francis expressed excitement about the opportunities to further expand platform adoption in 2025, supported by reimbursement tailwinds, while advancing toward achieving positive annual AEBITDA and improving margins.

Industry Context

SI-BONE's focus on sacropelvic disorders and minimally invasive SI joint surgery positions it within a growing market for innovative medical devices. The company's expansion into adjacent markets, such as adult deformity and pelvic trauma, diversifies its revenue streams and addresses a broader range of patient needs.

Comparison to Industry Standards

• Comparing SI-BONE's growth to other medical device companies focused on surgical solutions, companies like Stryker and Zimmer Biomet, which have broader portfolios, often see more moderate growth rates.
• SI-BONE's 20% revenue growth for the year is strong compared to the overall medical device industry, which typically sees single-digit growth.
• The positive adjusted EBITDA in Q4 is a significant milestone, as many smaller medical device companies struggle to achieve profitability in their early stages.
• SI-BONE's gross margin of 79% is competitive within the medical device industry, indicating efficient cost management.

Stakeholder Impact

• Shareholders can expect continued growth and improved profitability.
• Employees may benefit from the company's success and expansion.
• Customers (physicians and patients) can anticipate further innovation and improved treatment options.
• Suppliers may see increased demand for SI-BONE's products.
• Creditors can be reassured by the company's strong financial position.

Next Steps

• SI-BONE will host a conference call to discuss the fourth quarter 2024 financial results on February 24, 2025.
• The company plans to further expand platform adoption in 2025.
• SI-BONE aims to achieve positive annual AEBITDA and improve margins in 2025.

Key Dates